Affinivax and Astellas presented data from a phase 2 trial evaluating ASP3772, a vaccine developed using Affinivax’s proprietary MAPS (Multiple Antigen-Presenting System) platform technology and designed to offer both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 was well tolerated and exhibited an antibody response to each of the 24 polysaccharides contained in the vaccine, as well as an additional antibody response to the conserved pneumococcal proteins. The data were delivered in an oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which took place online from July 9-12, 2021.
The Phase 2 trial was conducted in 503 adults 65 to 85 years of age who received one of three dose levels of ASP3772 (n=293), Prevnar13 (n=97) and Pneumovax23 (n=113 adults who were previously vaccinated with Prevnar13). The primary objective was to evaluate safety, tolerability and reactogenicity of ASP3772 compared to Prevnar13. The secondary objective was to evaluate the immunogenicity of ASP3772, versus Prevnar13 or Pneumovax23.
ASP3772 was well tolerated with mild and ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).